EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 22-Jun-2026 06:15 ET (22-Jun-2026 10:15 GMT/UTC)

Treatment strategies after denosumab discontinuation in non-metastatic breast cancer treated with AI

International Osteoporosis Foundation
Peer-Reviewed Publication

This narrative review by an expert International Osteoporosis Foundation (IOF) Working Group highlights an under-recognized bone health risk in women with early-stage, hormone receptor–positive breast cancer treated with aromatase inhibitors and denosumab. Although denosumab effectively prevents treatment-related bone loss and fractures, its benefits rapidly reverse upon discontinuation, unlike those of bisphosphonates. The review warns that stopping denosumab can trigger a rebound increase in bone turnover, rapid bone loss, and spontaneous vertebral fractures—even in women without prior osteoporosis—underscoring that clinicians should anticipate denosumab discontinuation from the moment therapy is initiated and ensure a structured transition to alternative antiresorptive treatment, The review also outlines areas in need of further research, providing a valuable framework for further research priorities.

Journal: Osteoporosis International

Production of 99Mo via photofission reaction in natural-uranium-bearing molten salt targets

Nuclear Science and Techniques
Peer-Reviewed Publication

Researchers have proposed a method for ⁹⁹Mo production via electron accelerator irradiation of a natural-uranium-bearing liquid molten salt target. This approach offers significant advantages, including low nuclear proliferation risk, online extraction capability, and low construction costs. Consequently, it provides a viable pathway for stable, large-scale ⁹⁹Mo production.

Journal: Nuclear Science and Techniques

Immunity against common virus leveraged against pancreatic cancer

University of California - San Diego
Peer-Reviewed Publication

UC San Diego researchers have harnessed the body's immune response to a common virus to shrink pancreatic tumors, offering hope for a new cancer treatment approach.

Journal: Journal for ImmunoTherapy of Cancer

Physical pressure on the brain triggers neurons’ self-destruction programming

University of Notre Dame
Peer-Reviewed Publication

An interdisciplinary team of researchers from the University of Notre Dame is investigating the mechanisms of neuron death caused by chronic compression — such as the pressure exerted by a brain tumor — to better understand how to prevent neuron loss.

Journal: Proceedings of the National Academy of Sciences

IRB Barcelona launches Spain’s first fully integrated Spatial Omics Platform

Institute for Research in Biomedicine (IRB Barcelona)
Business Announcement

IRB Barcelona inaugurates the country’s first end-to-end fully integrated spatial omics platform, enabling scientists to map biological activity directly within its original tissue context.

The Institute has invested more than €3 million to equip the platform with the latest spatial transcriptomics and spatial proteomics technologies, along with advanced image analysis and bioinformatics capabilities.

This strategic initiative unites five specialised Core Facilities to create a coordinated, end-to-end workflow supporting research and innovation across academic, clinical, and industry partners in Spain and beyond.

Study shows advanced PET/CT imaging can help improve long-term outcomes for men with recurrent prostate cancer

University of California - Los Angeles Health Sciences
Peer-Reviewed Publication

A five-year retrospective study shows that prostate-specific membrane antigen (PSMA) PET/CT scans can help doctors target treatment more precisely for men whose prostate cancer returns after surgery, improving long-term outcomes and potentially reducing unnecessary side effects.

Journal: Journal of the National Comprehensive Cancer Network

Dana-Farber research helps drive FDA label update for primary CNS lymphoma

Dana-Farber Cancer Institute
Business Announcement

Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system lymphoma, a rare and aggressive lymphoma of the brain and spinal cord. The change is expected to expand access to commercial CAR T-cell therapy for eligible patients with relapsed or refractory disease.

Early diagnosis key to improving childhood cancer survival

University College London
Peer-Reviewed Publication

Childhood cancers, survival rates, early diagnosis, comparing rates by geographical region

Journal: JAMA Network Open
Funder: CHILDREN with CANCER UK, Associazione Italiana per la Ricerca sul Cancro, National Institute for Health Research

First in-human study finds novel immune cell therapy is safe and effective in advanced lymphoma

University of Texas M. D. Anderson Cancer Center
Reports and Proceedings

In a first-in-human study, researchers at The University of Texas MD Anderson Cancer Center observed strong responses and early signs of antitumor activity in patients with difficult-to-treat non-Hodgkin lymphomas who received the novel cell therapy RB-1355. The therapy was effective for those who have relapsed after multiple treatments or no longer responded to standard-of-care options, such as CAR T cell therapy.

Mayo Clinic study finds chemotherapy before surgery improves survival in early-stage pancreatic cancer

Mayo Clinic
Peer-Reviewed Publication

A Mayo Clinic study is providing new insights into how treatment sequence can affect survival in patients with early-stage pancreatic cancer, suggesting that many patients may benefit from receiving chemotherapy before surgery.

Journal: Journal of the National Comprehensive Cancer Network